glp 1 fatty liver Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide Receptor Agonists in Nonalcoholic Disease New GLP-1 research to watch:

For healing applications, most acute injuries show substantial improvement by week 8 to 10

Transcription-coupled nucleotide excision repair and the transcriptional response to UV-Induced DNA damage

CMS Extends Medicares Short-Term Bridge Program for GLP-1 Obesity Drug Coverage The Centers for Medicare & Medicaid Services (CMS) has announced that its temporary program to cover GLP-1 drugs for obesity in Medicare, called the BALANCE model, will not launch as scheduled on January 1, 2027

It notes that visceral fat reduction often precedes visible scale changes, particularly for people starting at a higher BMI, who may also show slower percentage loss early on

They have documented availability of both semaglutide and tirzepatide products, and their pharmacists typically speak some English in tourist-adjacent locations